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Introduction
Organ transplantation across a species 
barrier—xenotransplantation—has 
been attempted for over a century. 
Given the rapidly increasing gap 
between the organs required and those 
available for transplantation, over 
the last 20 years xenotransplantation 
has been aggressively pursued 
as a promising supplement to 
allotransplantation (see Glossary).
Progress in this ﬁ  eld from the 
late eighties to the late nineties had 
been steady, but shrinking funding, 
ethical and regulatory issues, threats 
of transmission of infection, and 
diminished interest by industry have 
resulted in a signiﬁ  cant decline of 
enthusiasm in this ﬁ  eld. But the recent 
development of genetically modiﬁ  ed 
pigs that are more compatible with 
humans has reinstated hope for the 
success of xenotransplantation of 
organs. However, whether such genetic 
modiﬁ  cations are necessary to prevent 
xenograft rejection of porcine cells is 
questionable.
Early Experiments Using Small 
Animal Models
A signiﬁ  cant amount of information 
about the mechanism of solid organ 
xenograft rejection was gained 
from earlier experiments using 
small animal models. Experimental 
protocols were successfully generated 
to induce graft accommodation 
and donor-speciﬁ  c tolerance, the 
latter, for example, through the 
generation of microchimerism [1–6]. 
In accommodation studies, production 
of antibodies in transplanted animals 
was delayed, and when the antibodies 
were later allowed to return, the 
transplanted organ had developed 
a means of protection from these 
antibodies, thus preventing antibody-
mediated rejection [5,7]. In tolerance 
studies, the immune system of the 
recipient was manipulated so that 
it learned to recognize the foreign 
graft as self [1,3,4,8]. Costimulatory 
blockade and suppression of T and B 
cells were also successful in achieving 
long-term graft survival in small animal 
models [9–14].
Thus, work in small animal models 
of solid organ xenografts clearly 
showed that xenotransplantation 
initiates a variety of inﬂ  ammatory, 
immune, and coagulation responses, 
and the successful suppression of these 
responses encouraged researchers 
to move to larger animal models. 
Unfortunately, the task of extending 
graft survival in large animal models 
such as pig-to-nonhuman primate 
(NHP) has proven to be a tall order. 
The mechanism of rejection is found 
to be more complex and experiments 
using large animals have resulted 
in identiﬁ  cation of new pathways 
responsible for substantial anti-donor 
xenogeneic responses [15,16].
In this article, I discuss the 
lessons learned from large animal 
xenograft models and why the 
immunological barrier is still the most 
important hurdle preventing clinical 
xenotransplantation of organs. I also 
brieﬂ  y consider other barriers, such as 
ethical concerns and concerns about 
viral disease transmission.
Alternatives for Overcoming 
End-Stage Organ Failure
Patients requiring organ 
transplantation have limited options. 
For example, total artiﬁ  cial hearts or 
mechanical devices have great potential 
for replacing or improving the function 
of a diseased heart. However, while 
ventricular devices have helped patients 
with cardiac failure [17], implantation 
devices have suffered from thrombotic 
complications and are not yet proven 
suitable for replacing transplantation 
[18].
Autologous adult stem cell 
transplantation has garnered 
signiﬁ  cant interest over the past few 
years. This procedure has the potential 
to repair damage due to myocardial 
infarction and local defects [19–21]. 
Allogeneic stem cell transplantation 
may play a role in delaying the need 
for transplantation. However, neither 
of these methods have the potential to 
replace entire organs.
The idea of growing organs 
in culture dishes has fascinated 
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Glossary
Allogeneic: Two or more strains are 
stated to be allogeneic to each other 
when the genes at one or more loci 
are not identical in sequence in each 
organism.
Allotransplantation: Transplantation of 
an allograft.
Autologous: Derived from the same 
organism.
Heterotopic: Occurring in an abnormal 
position.
Microchimerism: The presence of 
two genetically distinct and separately 
derived populations of cells, one 
population being in low concentration, in 
the same individual or organ ( e.g., bone 
marrow).PLoS Medicine  |  www.plosmedicine.org 0430
scientists for years. Attempts to grow 
organs (e.g., kidneys) in vitro have 
yielded small sized organs that lack 
vascularization [22]. Attempts to grow 
organs in vivo, in which fetal tissue has 
been shown to grow into functional 
organs, have shown some promise. The 
progress in this ﬁ  eld is gradual but I 
believe that attempts to grow organs 
are further away from clinical practice 
than xenotransplantation. Considering 
all these options, xenotransplantation 
seems to be one of the most viable and 
complete options for replacing organs 
to treat end-stage diseases.
Mechanisms of Xenograft 
Rejection in Animal Models
Antibody-mediated rejection. In 
experimental xenotransplantation 
between discordant species, i.e., species 
that are phylogenetically distant, the 
graft undergoes hyperacute rejection 
(HAR) within minutes. In the pig-
to-NHP combination, an example of 
discordant species combination, HAR 
is primarily mediated by preformed 
xenogeneic natural antibody (XNA, 
predominantly IgM) against a galactose 
residue (Galactose alpha 1,3-Galactose 
[Gal]) expressed on pig vascular 
endothelium [23,24]. Gal is expressed 
by pigs and most other mammals 
[25,26]. Binding of XNA to Gal leads to 
activation of the complement cascade, 
which causes endothelial damage, 
thrombus formation, and ultimately 
a very rapid graft rejection within 
minutes [23,27,28].
If this antibody- and complement-
mediated rejection is averted by 
measures described below, the 
transplanted organ undergoes delayed 
xenograft rejection or acute vascular 
rejection [29]. In these cases, elicited 
( IgM and IgG) antibodies recognize 
Gal and other non-Gal antigens on the 
vascular endothelium leading to its 
activation and rejection of xenografts 
[30].
Inefﬁ  cient regulation of homeostasis 
leading to intravascular coagulation. 
Intravascular coagulation is triggered 
by either antibody/cell-mediated 
damage of the endothelium or by 
coagulation factor incompatibilities 
between two species, and plays a 
signiﬁ  cant role in xenograft rejection. 
On activation by either antibody 
binding, or directly by T cells, NK cells, 
or macrophages, endothelium changes 
from its anticoagulant state to a 
procoagulant state by up regulation of 
von Willebrand factor and production 
of tissue factor leading to thrombus 
formation, hemorrhage, and rejection 
of the graft.
The molecular incompatibilities 
of coagulation and complement 
systems further contribute to the 
rejection process in many porcine-to-
NHP systems. For example, porcine 
thrombomodulin cannot bind to 
NHP thrombin, and therefore cannot 
activate protein C and prevent 
thrombosis [31].
Rejection of Gal knockout pig 
xenografts. Recently pigs have been 
generated in which the enzyme 1,3-
galactosyltransferase (GT) gene, which 
encodes the enzyme responsible for 
adding Gal residues to many cell 
surface molecules, has been disrupted. 
When organs from these Gal-deﬁ  cient 
pigs are transplanted into baboons, 
there is no activation of complement 
due to the binding of preformed 
anti-Gal antibody and hyperacute 
rejection is prevented. Nevertheless, 
antibodies to non-Gal antigens, which 
can also directly activate endothelium, 
and persistence of coagulation 
incompatibilities leads to graft rejection 
[15]. These non-Gal antigens have not 
been fully characterized yet and their 
potential role in xenograft rejection is 
under investigation. In Gal knockout 
(KO) pigs, some investigators have 
shown an alternate mechanism of 
surface expression of Gal, suggesting 
that elimination of Gal is not complete 
[32].
Cell-mediated rejection. In vitro 
studies analyzing the human response 
to porcine antigens indicates that 
human T cells can directly recognize 
porcine major histocompatibility 
complex, swine leukocyte antigen I 
& II, and can also recognize porcine 
antigens indirectly in the context of 
self major histocompatibility complex, 
human leukocyte antigen [33]. A 
recent paper by Davila et al. shows 
the induction of cytotoxic pig-speciﬁ  c 
CD4+CD28- lymphocytes capable of 
direct tissue destruction [34]. Multiple 
NK cell-mediated xenograft rejection 
pathways also exist and complicate 
efforts to neutralize the potent anti-
xenograft activity of NK cells. Recent 
studies using Gal-/- porcine endothelial 
cells showed resistance to NK-
mediated antibody-dependent cellular 
cytotoxicity, but susceptibility to direct 
NK cell lysis [35,36]. Macrophages have 
also been shown to target and directly 
destroy islet xenografts [37].
Large Animal Models of 
Xenotransplantation: Recent 
Progress and Limitations
Cellular (islet) transplantation. The 
most promising reports have come 
from transplanting wild type porcine 
islets in NHP for the treatment of 
diabetes, where complete reversal of 
diabetes was shown consistently for 
over 100 days [38,39]. Much evidence 
suggests that adult porcine islets, unlike 
endothelial cells and many other cell 
types, do not express the Gal epitope, 
and are not susceptible to XNA-
mediated hyperacute rejection.
But there were a few drawbacks 
in both of these studies [38,39]. 
First, a much larger number of 
islets compared to the number 
used in clinical transplantation of 
human islets were infused to control 
hyperglycemic states. Second, the level 
of immunosuppression used in the 
NHP studies would be unacceptable in 
humans. For the effective use of this 
method in clinics, a more acceptable 
immunosuppressive regimen will 
be needed and if a larger dose of 
xeno islets is required to overcome 
hyperglycemia, an alternate site, 
such as the omental pouch, could be 
considered to avoid compromising 
liver function. To avoid immune 
rejection, porcine islets have also been 
transplanted successfully using alginate 
encapsulation; while this method offers 
promise, additional work is needed 
[40].
Solid organ transplantation. Mixed 
results have emerged from experiments 
using genetically modiﬁ  ed pig-to-
baboon organ transplantation. To date, 
only two groups have reported long-
term survival (over three months) of 
heterotopic porcine cardiac xenografts 
for in baboons. McGregor et al. have 
shown long-term survival of human 
CD46 transgenic pig hearts in baboons 
by using synthetic Gal conjugate 
(TPC) and strong immunosuppression 
[41,42]. Kuwaki et al. transplanted 
Gal KO pig hearts heterotopically into 
baboon recipients and demonstrated 
graft survival of over six months with 
costimulation blockade and immune 
suppression [43,44]. McGregor et al. 
have recently reported (unpublished 
data; World Transplant Congress, 
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Boston, MA) survival of orthotropic 
cardiac xenografts with the longest 
graft survival of over 60 days, indicating 
the ability of pig heart to sustain life of 
recipient baboon.
Recently developed techniques of 
vascular thymic transplantation are 
also a major step towards tolerance 
induction to xenografted kidneys 
[45,46]. Successful prolongation of pig 
kidney graft survival by simultaneous 
transplantation of pig thymus has also 
been reported using Gal KO pigs as 
source animals [47]. However, the 
extensive immunosuppression used 
in these experiments signiﬁ  cantly 
increased the mortality rate due to 
infections.
Several other manipulations 
targeting speciﬁ  c causes of rejection 
have been developed to overcome 
xenograft rejection in large animal 
models. Some of these approaches and 
their resultant effects are described 
below (see also Figure 1).
Targeting antibody-mediated 
rejection. Investigators have successfully 
delayed HAR by immunoadsorption of 
antibody on columns or by blocking the 
epitope binding with GAS 914 or TPC 
(Gal-Polyethylene glycol conjugates) 
[41,48–50]. But reemergence of 
antibodies had not been properly 
controlled and still posed a credible 
problem.
In experiments using Gal-deﬁ  cient 
pigs as sources, and in recipients 
in which anti-Gal antibodies were 
neutralized, antibodies against non-Gal 
antigens have induced acute xenograft 
rejection [15,51]. Kidneys transplanted 
into baboons from either Gal KO pigs 
or wild type pigs with Gal neutralized by 
synthetic Gal conjugates are subject to 
acute rejection by non-Gal antibodies 
[15]. The results of this study [15] and 
studies performed by other groups 
suggests that when Gal is present, anti-
Gal is the primary antibody involved 
in rejection, but in its absence other 
non-Gal antibodies play a prominent 
role in xenograft rejection. Anti-CD20 
antibody has been effectively used to 
eliminate antibody-producing B cells in 
allotransplantation and in therapies for 
several leukemias. When this antibody 
was used for an extended period of 
time to avoid xenograft rejection, it 
resulted in serious infections, thus 
limiting its use to induction therapy. 
CD20 is not expressed on memory B 
cells, therefore the antibody against this 
molecule is unable to suppress anti-pig 
antibody production by these cells[52].
Suppressing complement and 
thromboembolism. Complement is a 
doi:10.1371/journal.pmed.0040075.g001
Figure 1. Current Methods to Prevent Xenograft Rejection
TFPI, tissue factor pathway inhibitor.
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major contributor to both antibody-
mediated rejection and coagulopathies 
responsible for xenograft rejection. 
Therefore, measures to prevent 
complement activation included use 
of soluble complement receptor 1 
(sCR1) [53], cobra venom factor 
(CVF) [54], and transgenic expression 
of human complement regulatory 
proteins such as decay accelerating 
factor (CD55) [55], CD59 [56], and 
membrane cofactor protein (CD46) 
[57]. Expression of decay accelerating 
factor prevented HAR to some extent 
[58], but was not sufﬁ  cient to prevent 
microangiopathic coagulopathy [59]. 
Transgenic expression of human 
CD46 along with the use of strong 
immunosuppressive agents could 
partially inhibit graft rejection [42]. 
Triple expression of human CD55/
CD59/ alpha 1,2-fucosyltransferase 
(HT) (alpha 1,2-fucosyltransferase 
competes with GT for substrate to 
reduce Gal expression) also averted 
HAR, but was also not successful in 
signiﬁ  cantly prolonging the graft 
survival [60].
Drug strategies to prevent 
thromboembolism included warfarin 
or low molecular weight heparin [61], 
aspirin [62], and anti-platelet therapy 
with aspirin and clopidogrel [63], but 
none of them were able to signiﬁ  cantly 
prolong graft survival. Genetic 
modiﬁ  cations to prevent thrombosis 
include transgenic expression of 
human tissue factor pathway inhibitor, 
CD39, or thrombomodulin. Any 
reports using these transgenic factors 
in large animal models are yet to be 
published. Coagulopathy has also 
been associated with latent porcine 
cytomegalovirus (pCMV) infections, 
but early weaning of pigs has prevented 
activation of pCMV infections, and 
consumptive coagulopathy was thereby 
averted [64].
Costimulation blockade. Anti-
CD154 was used by some groups to 
prolong graft survival [38,65–67], but 
thromboembolic complications limited 
the successful use of this agent [68,69]. 
Other methods of costimulation 
blockade that work well in inducing 
tolerance in small xenograft models 
have not proven successful in 
prolonging pig-to-baboon cardiac 
xenograft [67].
Most of the above techniques 
currently used to over come xenograft 
rejection are summarized in Figure 1.
Beyond Immunological Barriers: 
Concerns about Ethics and Viruses
All the current regimens used to 
prolong xenograft survival involve 
vigorous immune suppression leading 
to an immunocompromised recipient. 
This immune suppression could 
result in infection by pathogens not 
normally associated with human 
disease or by newly emerging 
infectious agents. Categories of 
potential pathogens are discussed 
elsewhere [70]. The demonstration 
that porcine endogenous retroviruses 
(PERVs) infect human cells in vitro 
has raised concerns about disease 
transmission by retroviruses through 
xenotransplantation [71].
But selective breeding techniques 
may eliminate a large number of 
potential pathogens, including 
pCMV, and possibly reduce infectious 
endogenous retroviruses. Swine that do 
not express PERVs that are infectious 
for human cells have been identiﬁ  ed 
[72]. Long-term retrospective studies 
of patients treated with pig tissues 
have not found any evidence of PERV 
infection in any of the patients tested 
[73,74]. Antibodies against the highly 
conserved epitopes encoded by the 
retroviral genome have been shown to 
neutralize PERV infectivity, suggesting 
that there may be a basis for producing 
a PERV vaccine [75].
However, the risk of infection 
via xenotransplantation could be 
perceived differently by patients with 
end-stage heart disease or a patient 
with kidney failure inadequately 
controlled by dialysis. New viruses and 
other pathogens continue to infect 
human beings. Whether the risk of 
transmission of these pathogens will 
increase with xenotransplantation 
is not yet known. But the risk can 
be anticipated, and thus prepared 
for. A long-term careful follow-up of 
transplanted patients will be required 
to monitor for infection by latent 
viruses and other pathogens. A timely 
intervention would be important to 
treat the infection and control its 
spread to other individuals.
Other barriers to clinical 
xenotransplantation include ethical 
concerns, including the objection 
of animal rights proponents to the 
use and genetic modiﬁ  cation of pigs. 
Commercial considerations (e.g., high 
cost) and regulatory requirements to 
ensure safety and the potential for 
efﬁ  cacy may also play a signiﬁ  cant 
role in delaying the transition of 
xenotransplantation from bench to 
bedside.
The Next Steps
It is evident from the progress to date 
that there are several mechanisms of 
xenograft rejection which still must 
be overcome and which will require 
extensive investigations to make 
xenotransplantation a clinical reality. 
There are fewer hurdles to worry 
about in xenogeneic cellular/islet 
transplantation, which therefore has 
greater potential for reaching clinics 
than solid organ xenotransplantation.
For organ xenotransplantation, just 
replacing one immunosuppressive 
agent with another may not serve 
the purpose. Serious attempts 
should be made to induce tolerance 
to xenografts, especially for B 
lymphocyte mediated immunity, 
or to further modify the genetic 
makeup of the Gal KO pig to make 
it less immunogenic in both NHP 
and humans. More experiments 
are needed with life supporting 
organ transplantation to determine 
the physiologic restrictions of this 
procedure. Further, cross species 
transmission of pathogens should 
be studied in greater depth as this 
issue will also limit the transition of 
xenotransplantation to clinics.
With diminishing industry support 
and limited funding from granting 
agencies, it has become more evident 
that ﬁ  nding a solution to xenograft 
rejection is not within the scope of one 
investigator or laboratory. Therefore, it 
is imperative that major groups working 
on xenotransplantation share their 
information and expertise to formalize 
a joint approach to make this unique 
ﬁ  eld a clinical reality.
I believe that the research in 
this ﬁ  eld is progressing in the right 
direction and, in the course of 
seeking to solve xenograft rejection, 
has signiﬁ  cantly advanced our 
understanding of several important 
immunological mechanisms, including 
the role of anti-carbohydrate 
antibodies, memory B cells, 
coagulation cascades, and cancer 
therapy. There is a fair amount of 
optimism that with careful planning 
and a coordinated effort, the dream 
of clinical xenotransplantation can be 
achieved.  
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